Heymann Dominique, Rédini Françoise
INSERM, UMR 957, Faculty of Medicine, University of Nantes , Nantes, France ; Faculté de Médecine, Université de Nantes, Nantes Atlantique Universités, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives , Nantes, France ; University Hospital, Hôtel Dieu , CHU de Nantes, France ; Equipe Labellisée Ligue Nationale Contre le Cancer 2012 , Nantes, France.
Bonekey Rep. 2013 Jul 17;2:378. doi: 10.1038/bonekey.2013.112.
Bone sarcomas include a very large number of tumour subtypes, which originate form bone and more particularly from mesenchymal stem cell lineage. Osteosarcoma, Ewing's sarcoma and chondrosarcoma, the three main bone sarcoma entities develop in a favourable microenvironment composed by bone cells, blood vessels, immune cells, based on the 'seed and soil theory'. Current therapy associates surgery and chemotherapy, however, bone sarcomas remain diseases with high morbidity and mortality especially in children and adolescents. In the past decade, various new therapeutic approaches emerged and target the tumour niche or/and directly the tumour cells by acting on signalling/metabolic pathways involved in cell proliferation, apoptosis or drug resistance. The present review gives a brief overview from basic to clinical assessment of the main targeted therapies of bone sarcoma cells.
骨肉瘤包括大量肿瘤亚型,它们起源于骨,更具体地说起源于间充质干细胞谱系。骨肉瘤、尤因肉瘤和软骨肉瘤这三种主要的骨肉瘤实体,基于“种子与土壤理论”,在由骨细胞、血管、免疫细胞组成的有利微环境中发展。目前的治疗方法包括手术和化疗,然而,骨肉瘤仍然是发病率和死亡率很高的疾病,尤其是在儿童和青少年中。在过去十年中,出现了各种新的治疗方法,这些方法通过作用于参与细胞增殖、凋亡或耐药性的信号/代谢途径,靶向肿瘤微环境或/和直接靶向肿瘤细胞。本综述简要概述了骨肉瘤细胞主要靶向治疗从基础到临床的评估情况。